Alerta

C3D4 Human Cell Model for MERS and SARS-C0V-2 Infection

Resumen de: US2025123269A1

A robust human cell culture model permissive to both SARS-COV-2 variants and MERS-COV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-COV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-COV-2 spike protein. By contrast, MERS-COV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549-ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 (“ACE2plusC3D4”) are highly susceptible to MERS-COV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

DYRK/CLK PROTACS AND USES THEREOF

Resumen de: WO2025080753A1

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, HIPKs, and/or CMGC kinases leading to inhibition of WNT signaling. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, HIPKs, and/or CMGC kinases leading to inhibition of WNT signaling, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer, acute myeloid leukemia, myelodysplastic syndrome), a viral infection (e.g., SARS-CoV-2 infection (e.g., COVID-19)), and other diseases.

METHOD FOR DETERMINING THE LEVEL OF RISK OF SEVERE COVID-19 DISEASE IN A PATIENT

Resumen de: WO2025080149A1

A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.

REAL-TIME DISEASE OUTBREAK PHYLOGENETIC ANALYSIS

Resumen de: WO2025081000A1

To infer transmission links using within-host variation, Applicants first developed a statistical model of minor variant frequencies, which Applicants fit to a dataset of 134,682 SARS- CoV-2 genomes from Massachusetts, USA. Applicants then combined this model with a stochastic epidemic process to develop a hierarchical Bayesian statistical model of viral outbreaks. After validating the approach on both synthetic and real outbreak datasets, Applicants applied the tool to 5,692 outbreak clusters among the 134,682 Massachusetts genomes. Applicants found that informative sub-consensus variants are relatively rare in outbreaks, but that when they do occur, they significantly help resolve transmission networks. Applicants methods and results demonstrate the utility of within-host variation for transmission inference of SARS-CoV-2 and other pathogens, stressing the importance of pathogen sequencing in epidemiology and public health.

KIT AND METHOD FOR DETERMINING BY POLYMERASE CHAIN REACTION THE ALLELE CONFIGURATION AT THE RS143334143 LOCUS AND AT THE RS74956615 LOCUS

Resumen de: WO2025080150A1

The invention relates to a kit comprising a primer pair and optionally probe(s) for assaying the presence of two genetic polymorphisms, namely rs143334143 locus and at the rs74956615 whose occurrence significantly modifies the course of (indicates the risk of a severe) COVID-19 disease. The invention also relates to a method with the same purpose. The kit and the method represent new tools in the public health protection against COVID-19 disease.

ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF

Resumen de: US2025123274A1

Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.

VACCINES AGAINST CORONAVIRUS AND METHODS OF USE

Resumen de: US2025121054A1

Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

VACCINE COMPOSITIONS AND THEIR USE

Resumen de: US2025121053A1

The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.

SARS-COV-2 VACCINES

Resumen de: US2025121052A1

Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

PROTEIN BASED VACCINE AND PRODUCTION METHOD THEREOF FOR SARS COV-2

Resumen de: US2025122243A1

The present invention is directed to a composition, mammalian cell and vector, and a method for the production of, and method of treatment with, a recombinant protein vaccine in a mammalian cell line. The methods and compositions are particularly useful for generating the stable expression of a recombinant protein vaccine of interest. The invention is particularly useful for the production of vaccines to aid in protection against viral pathogens for vertebrates, in particular mammalians, especially humans. The mammalian cell for producing a protein of interest comprises: a plasmid encoded with a nucleotide sequence encoding one or more epitopes or subunits of the SARS-CoV-2 that are embedded in the nucleotide sequence encoding a detoxified recombinant tetanus toxin (DrTeNT).

Protease Inhibitors as Antivirals

Resumen de: US2025122153A1

Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2

Resumen de: AU2023283718A1

The present disclosure relates to methods for treating viral infections in a patient that is not pregnant. Also provided are combination treatments for viral infections in a human in need thereof.

A bacteriophage-based, needle and adjuvant-free, mucosal Covid-19 vaccine

Resumen de: GB2634646A

A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger CD4+ and CD8+ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.

EVOLUTION OF FLUOROGENIC SENSORS

Resumen de: AU2023353878A1

Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (

SYNTHESIS AND EVALUATION OF 9-AMINOACRIDINES WITH SARS-COV-2 ANTIVIRAL ACTIVITY

Resumen de: WO2025076406A1

The synthesis and characterization of a series of derivatives and analogs based on the 9-aminoacridine scaffold shared by antimalarial drugs quinacrine and pyronaridine are described. Also described is the structure-activity relationship of these compounds against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease of 2019 (COVID-19). Several compounds displayed potent in vitro activity, with 50% inhibitory concentrations below 1 micromolar.

CORONAVIRUS SPIKE PROTEIN VARIANTS

Resumen de: WO2025075129A1

Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections.　The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.

PREDICTING SUSCEPTIBILITY OF LIVING ORGANISMS TO MEDICAL CONDITIONS USING MACHINE LEARNING MODELS

Resumen de: US2025114044A1

Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.

NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS

Resumen de: US2025114389A1

Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2

Resumen de: US2025114394A1

The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Composition For Treating and Preventing COVID-19 and Method For Treatment of COVID-19

Resumen de: US2025114425A1

A composition for the treatment of or prevention of COVID-19 or long COVID may be a mixture of: water; green tea; lemon juice; red onions; and garlic. One embodiment of the composition may be made by including a plurality of bags of green tea, sliced lemons, lemon juice, cut red onion pieces, and a plurality of cut garlic pieces in water, boiling the composition for about 30 minutes, and then straining the composition. A piece of smashed ginger may be added to the composition prior to boiling. A cup of the composition may be drunk three or more times a day to treat a person having COVID-19, or a cup or more of the composition may be drunk daily to prevent COVID-19.

USE OF BOSWELLIA FOR TREATING SARS-COV-2 INFECTION

Resumen de: US2025114418A1

The present invention relates to the use of extracts from Boswellia species and pharmaceutical compositions comprising Boswellia extracts in the treatment of SARS-CoV-2 infection and related medical conditions.

EXTRACELLULAR VESICLES FOR THERAPY

Resumen de: US2025114445A1

The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, e.g., infectious diseases.

MULTIPLEXED DIAGNOSTIC ASSAY DEVICE

Resumen de: US2025116668A1

Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. In some embodiments the devices are configured to process a bioaerosol sample. In some embodiments the diagnostic assay devices may be multiplexed and may be used for detecting the presence of two or more analytes in a sample solution. The diagnostic devices may be used, for example, to identify the presence of one or more of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.

METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION

Resumen de: US2025116673A1

Disclosed are methods for identifying or determining whether a subject exhibits a CD4+ memory T cell response to SARS-CoV-2 infection or vaccination, assessing the efficacy of a SARS-CoV-2 vaccine, and developing personalized SARS-CoV-2 treatment plans by detecting the presence and/or quantity of a particular T cell receptor a chain that recognizes a specific Spike protein epitope.

AN ISOLATED POLYPEPTIDE OR ANTIGENIC FRAGMENT THEREOF AND ITS USES FOR DIAGNOSING OR PREDICTING A DISEASE SUCH AS LONG COVID OR POST-VAC-SYNDROME

Nº publicación: WO2025073771A1 10/04/2025

Solicitante:

UNIV REGENSBURG IN VERTRETUNG DES FREISTAATES BAYERN [DE]
UNIV REGENSBURG [DE]
UNIVERSITAET REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN,
UNIVERSITAETSKLINIKUM REGENSBURG

Resumen de: WO2025073771A1

The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.